RxDoctor Payments Data

Scott Ungar, DO

Nephrology · Phoenix, AZNPI 1306075924

Payments from drug & device makers

$2,005in general payments, 2019–2025

Across 38 payments — averaging $52.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$808
  • Abiomed$294
  • Johnson & Johnson$221
  • Otsuka America Pharmaceutical, Inc.$218
  • AstraZeneca$154
  • Boston Scientific$121
  • plus $189 from 5 others

What the payments were for

  • Food & beverage$1,94497%
  • Education$613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,005 in reported general payments places this provider in the 40th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$121,831
Medicare patients
277
Services billed
1,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol96$67,404
LokelmaSodium Zirconium Cyclosilicate71$50,064
RetacritEpoetin Alfa-Epbx37$21,904
DapagliflozinDapagliflozin Propanediol12$7,277
JardianceEmpagliflozin12$6,947
Sevelamer Carbonate11$5,968
Allopurinol21$2,675
Bumetanide16$583
Eplerenone12$532
Losartan Potassium43$499
Calcitriol19$477
Carvedilol37$328
Potassium Chloride17$278
Amlodipine Besylate52$271
Doxazosin Mesylate12$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$154$117,468167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 259 nephrology providers in Arizona.

Other nephrology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →